[LCID Study Number: 2018-025]

The primary objective of this study is to evaluate the safety of regorafenib in patients with hepatocellular carcinoma. Safety will be measured in the frequency of treatment related adverse events. Researchers will also evaluate overall survival and progression free survival of patients.

The primary objective of this study is to evaluate the safety of regorafenib in patients with hepatocellular carcinoma. Safety will be measured in the frequency of treatment related adverse events. Researchers will also evaluate overall survival and progression free survival of patients.

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-2734